Guangzhou Lupeng Pharmaceutical Company LTD. clinical trials

A subsidiary of Lupeng Pharmaceutical Ltd.

The registry lists 16 studies whose lead sponsor is Guangzhou Lupeng Pharmaceutical Company LTD.. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Lupeng Pharmaceutical Ltd. studies →

• A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingNCT04993690Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingNCT05641259Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT07570017Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingNCT07776743Phase 2

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT07609823Phase 2

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib TabletRecruitingNCT07374224Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07377578Phase 3

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Phase 2

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06251180Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingNCT05716087Phase 2

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of LP-118 in Patients With Advanced TumorsCompletedNCT05025358Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of LP-128 Capsules in Healthy SubjectsActive, not recruitingNCT05130567Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• The Mass Balance Study of LP-168 in Healthy SubjectsCompletedNCT06126861Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedNCT05917964Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.

• A Study of LP-168 in Healthy VolunteersCompletedNCT05432713Phase 1

  Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.